Fake Ozempic pens sending people to hospitals amid demand surge for GLP-1 drugs

Are fake Ozempic pens sending people to hospitals amid the surge in GLP-1 demand?Counterfeit GLP-1 receptor agonist pens, including products labelled as Ozempic, have been reported in parts of Europe. In this episode, we explain the risks of falsified medicines and how safe prescribing and dispensing are managed.In this episode, we cover:• What GLP-1 receptor agonists are (medicines used for type 2 diabetes and weight management)• Why high demand increases counterfeit risk• Dangers of fake pens: incorrect dosing, unknown ingredients, contamination• Reported adverse events linked to unverified products• How legitimate prescriptions are supplied through regulated EU pharmacies• How to identify authorised packaging and supply chains• Why buying from unverified online sellers is dangerous• Situations where prescription requests may be declinedDoctors assess diagnosis, HbA1c, BMI, medical history, pancreatitis risk, kidney function, and current medications before prescribing GLP-1 therapy. These medicines require ongoing monitoring and are not appropriate without clinical evaluation. Suspicion of counterfeit medication exposure or severe side effects requires urgent in-person medical care.This episode reflects how medication safety and metabolic treatment decisions are reviewed within structured medical assessment in European telemedicine at Mobi Doctor.Read the full medical guide here:https://www.mobidoctor.eu/blog/fake-ozempic-pens-sending-people-to-hospitals-amid-demand-surge-for-glp-1-drugs